These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 17938582

  • 21. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM.
    Oncogene; 2012 Nov 08; 31(45):4789-97. PubMed ID: 22266850
    [Abstract] [Full Text] [Related]

  • 22. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X.
    Cell Cycle; 2011 Dec 15; 10(24):4225-9. PubMed ID: 22134240
    [Abstract] [Full Text] [Related]

  • 23. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
    Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, Gao L, Tovar C, Lovey A, Wanner J, Vassilev LT.
    Proc Natl Acad Sci U S A; 2012 Jul 17; 109(29):11788-93. PubMed ID: 22745160
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA.
    Cell Cycle; 2009 Apr 15; 8(8):1176-84. PubMed ID: 19305137
    [Abstract] [Full Text] [Related]

  • 27. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A, Tabata Y, Aoki K, Sada A, Ohki R, Nagatoishi S, Tsumoto K, Wang S, Otani Y, Ohwada T.
    Chem Pharm Bull (Tokyo); 2021 Jul 01; 69(7):681-692. PubMed ID: 33952867
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.
    J Am Chem Soc; 2014 Dec 31; 136(52):18023-33. PubMed ID: 25453499
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J, Wang J, Zhang Q, Chen K, Zhu W.
    Sci Rep; 2015 Nov 30; 5():17421. PubMed ID: 26616018
    [Abstract] [Full Text] [Related]

  • 33. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.
    Int J Oncol; 2013 Dec 30; 43(6):1935-42. PubMed ID: 24126697
    [Abstract] [Full Text] [Related]

  • 34. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L, He G, Zhang P, Wang X, Jiang M, Yu L.
    Mol Biol Rep; 2011 Jan 30; 38(1):229-36. PubMed ID: 20333547
    [Abstract] [Full Text] [Related]

  • 35. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 36. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C, McDonnell JM.
    Future Med Chem; 2009 Sep 03; 1(6):1075-94. PubMed ID: 21425995
    [Abstract] [Full Text] [Related]

  • 37. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M, Barcherini V, Lopes EA, Santos MMM.
    Curr Top Med Chem; 2018 Sep 03; 18(8):647-660. PubMed ID: 29866007
    [Abstract] [Full Text] [Related]

  • 38. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
    Su A, Wang S, Sada A, Otani Y, Zhai L, Liu X, Sayama M, Ohki R, Ohwada T.
    Chem Pharm Bull (Tokyo); 2019 Sep 03; 67(10):1139-1143. PubMed ID: 31582633
    [Abstract] [Full Text] [Related]

  • 39. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.
    Mol Oncol; 2017 Jun 03; 11(6):612-627. PubMed ID: 28296148
    [Abstract] [Full Text] [Related]

  • 40. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR, Ban D, Min J, Mayasundari A, Min L, Finch KE, Griffiths L, Bharatham N, Bashford D, Kiplin Guy R, Dyer MA, Kriwacki RW.
    J Mol Biol; 2016 Mar 27; 428(6):1290-1303. PubMed ID: 26812210
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.